<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20201201049551N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2020-12-08</date_registration>
      <primary_sponsor>Ahvaz University of Medical Sciences</primary_sponsor>
      <public_title>Comparison of two methods with and without creasing of part of the stomach in patients with morbid obesity</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of Roux-en-Y Gastric Bypass techniques with and without distal gastric plication  in Patients with morbid obesity referring to the hospitals affiliated to the Jundishapur University of Medical Sciences, Ahvaz during 2019-2020</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2020-12-09</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>40</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/52672</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Simple randomization based on random numbers table, In this way, we put a set of numbers in a completely random order without any pattern or order, set the table numbers to read from above. For intervention group we consider even numbers and for control group we consider individual numbers. Then we place one of the numbers up and down, register the number and assign it to one of the intervention or control groups, Blinding description: First, the study groups are explained to the participants, then, without knowing the name of the group, they enter one of the study groups.Participants and outcome assessors are not aware of any study group names.</study_design>
      <phase>2-3</phase>
      <hc_freetext>Morbid obesity.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Gastric bypass by distal plication method, in the Roux-en-Y method with distal gastric plication, the gastric puncture is about 25 ml and the biliopancreatic length is 50 cm. That like the standard method,only in this method, the stomach separated from the proximal part is folded together with a number of 2-0 nylon thread.The remaining stomach volume is 25 ml. Intervention 2: Control group: Gastric bypass by standard method without plication, in the Roux-en-Y method with distal gastric plication, the gastric puncture is about 25 ml and the biliopancreatic length is 50 cm  First, it is cut transversely to a distance of 5 cm from the GEJ in the form of a gastric tube, then the stomach is cut longitudinally to the cardia with a lumen 3 cm in diameter. The volume of the remaining stomach is 25 ml, which is inserted into the small intestine 80-120 cm in the distal position of the small intestine after anastomosis with the help of 2-0 Continius prolen.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
The whole data can be shared after unidentifiable people.

When:
Start the access period 6 months after printing the results

To whom:
Only available to scholars working in academic and academic institutions

Conditions:
Employed in research centers

Where to obtain:
Person responsible for scientific inquiries

How to obtain:
Send email to person responsible for scientific inquiries

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Mehdi Askari M.D</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Farvardin St.</address>
        <city>Ahvaz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>33118-61357</zip>
        <telephone>+98 61 3374 3001</telephone>
        <email>askari-m@ajums.ac.ir</email>
        <affiliation>Ahvaz University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Mehdi Askari M.D</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Farvardin St.</address>
        <city>Ahvaz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>33118-61357</zip>
        <telephone>+98 61 3374 3001</telephone>
        <email>askari-m@ajums.ac.ir</email>
        <affiliation>Ahvaz University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Age 18-65 years
Obesity with a BMI of more than 35 with comorbidity disease or more than 40 kg / m2
Obesity with comorbidity diseases
Patients with consent to participate in the study</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>65 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Debilitating diseases, including cancer, tuberculosis, AIDS
Having diseases that limit patient-physician communication, such as Alzheimer's
Recorded history of mental illness (major depression or uncontrolled psychosis)
Drug and alcohol abuse
Severe heart disease with risk of anesthesia
Severe coagulopathy
Not accepting nutritional orders
History of gastric surgery or antireflux surgery
High-grade dysplasia in Barrett's esophagus
Severe iron deficiency anemia
Distal lesions of the stomach or duodenum require follow-up
Patients with no consent to participate in the study</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>Z68. 41</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Body mass index (BMI) 40.0-44.9, adult.</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Surgery</i_code>
      <i_code>Treatment - Surgery</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Gastric bypass by distal plication method, in the Roux-en-Y method with distal gastric plication, the gastric puncture is about 25 ml and the biliopancreatic length is 50 cm. That like the standard method,only in this method, the stomach separated from the proximal part is folded together with a number of 2-0 nylon thread.The remaining stomach volume is 25 ml.</i_keyword>
      <i_keyword>Control group: Gastric bypass by standard method without plication, in the Roux-en-Y method with distal gastric plication, the gastric puncture is about 25 ml and the biliopancreatic length is 50 cm  First, it is cut transversely to a distance of 5 cm from the GEJ in the form of a gastric tube, then the stomach is cut longitudinally to the cardia with a lumen 3 cm in diameter. The volume of the remaining stomach is 25 ml, which is inserted into the small intestine 80-120 cm in the distal position of the small intestine after anastomosis with the help of 2-0 Continius prolen.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Weight Loss. Timepoint: Two weeks, 1,2,6, 12 months after surgery. Method of measurement: The rate of weight loss two weeks after surgery is 4%, 1 month after 8%, 3 months after 18%, 6 months after 30%, 12 months after 40% relative to baseline weight.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>The amount of ghrelin hormone. Timepoint: Six, 12 months after surgery. Method of measurement: Pg/mL.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Ahvaz University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2019-11-08</approval_date>
        <contact_name>Ethics committee of Ahvaz Jundishapur University of Medical Sciences</contact_name>
        <contact_address>Vice Chancellor for Research and Technology Ahvaz Jundishapur University of Medical Sciences, University City Ahvaz Khouzestan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
